Literature DB >> 15054646

Two-hour post-dose cyclosporin A levels in adolescent renal transplant recipients in the late post-transplant period.

Salih Kavukçu1, Alper Soylu, Mehmet Türkmen, Belde Kasap, Mukaddes Gümüştekin, Hüseyin Gülay.   

Abstract

Although the success of renal transplantation is closely linked to the immunosuppression provided by cyclosporin A (CsA), the best way to monitor the blood levels of CsA is still not clear. Trough CsA levels (C(0)) are commonly used, but the 2-h post-dose CsA levels (C(2)) are reported to correlate better with area under the curve. The aim of this study was to evaluate the correlation of C(2) levels with allograft function in adolescent renal transplant recipients in the late post-transplant period (6 months after transplantation) compared with C(0 )levels. The data of 17 adolescent renal transplant recipients (12 males, 5 females) were evaluated retrospectively. The mean age at the time of transplantation was 15.212+/-2.918 years and the mean follow-up period was 53.172+/-34.090 months. C(0) levels correlated with oral CsA and diltiazem doses, while C(2) levels exhibited no correlation. When C(2) levels were classified as 0-400, 401-800, and 801-1200 ng/ml, no statistically significant difference was found between these groups with respect to glomerular filtration rate (P=0.830). Although 82% of the patients had C(2 )beneath the therapeutic level (<800 ng/ml), none had an acute rejection episode. In conclusion, optimum C(2) levels could be different from levels in the adult population. Furthermore, the correlation of C(2) levels with CsA dose seems to be weaker than in the adult population. Thus, further studies are needed to determine a more reliable predictor for CsA dose monitoring and target blood CsA levels in adolescent patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15054646     DOI: 10.1007/s00467-004-1452-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  29 in total

1.  Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study.

Authors:  Kamran Mahalati; Philip Belitsky; Kenneth West; Bryce Kiberd; Albert Fraser; Ingrid Sketris; Alan S Macdonald; Vivian McAlister; Joseph Lawen
Journal:  J Am Soc Nephrol       Date:  2001-04       Impact factor: 10.121

2.  Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen.

Authors:  R Sindhi; M F LaVia; E Paulling; J McMichael; G Burckart; S Shaw; L A Sindhi; R Livingston; S Sehgal; J Jaffe
Journal:  Transplantation       Date:  2000-02-15       Impact factor: 4.939

3.  Formulation of diltiazem affects cyclosporin-sparing activity.

Authors:  T E Jones; R G Morris; T H Mathew
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 4.  Cyclosporin pharmacokinetics in paediatric transplant recipients.

Authors:  G F Cooney; K Habucky; K Hoppu
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

5.  The temporal profile of calcineurin inhibition by cyclosporine in vivo.

Authors:  P F Halloran; L M Helms; L Kung; J Noujaim
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

Review 6.  Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel.

Authors:  M Oellerich; V W Armstrong; B Kahan; L Shaw; D W Holt; R Yatscoff; A Lindholm; P Halloran; K Gallicano; K Wonigeit
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

Review 7.  Treatment of hypertension in renal allograft patients: does drug selection make a difference?

Authors:  J J Curtis
Journal:  Kidney Int Suppl       Date:  1997-12       Impact factor: 10.545

8.  A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.

Authors:  P Keown; D Landsberg; P Halloran; A Shoker; D Rush; J Jeffery; D Russell; C Stiller; N Muirhead; E Cole; L Paul; J Zaltzman; R Loertscher; P Daloze; R Dandavino; A Boucher; P Handa; J Lawen; P Belitsky; P Parfrey
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

9.  Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

Authors:  M Cantarovich; J G Besner; J S Barkun; E Elstein; R Loertscher
Journal:  Clin Transplant       Date:  1998-06       Impact factor: 2.863

10.  Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.

Authors:  Edward Cole; Nava Maham; Carl Cardella; Daniel Cattran; Stanley Fenton; Jayne Hamel; Catherine O'Grady; Robert Smith
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

View more
  1 in total

1.  Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Masaru Takada; Yoshiyuki Ohtomo; Shunji Akashi; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-05-26       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.